Savant Capital LLC Purchases 13,839 Shares of AbbVie Inc. $ABBV

Savant Capital LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 8.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 185,554 shares of the company’s stock after purchasing an additional 13,839 shares during the period. Savant Capital LLC’s holdings in AbbVie were worth $42,963,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Shayne & Jacobs LLC acquired a new stake in shares of AbbVie during the third quarter worth about $210,000. J.W. Cole Advisors Inc. raised its holdings in AbbVie by 0.5% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 89,113 shares of the company’s stock worth $20,633,000 after buying an additional 446 shares during the period. Payne Capital LLC bought a new position in AbbVie in the third quarter valued at approximately $307,000. Baker Boyer National Bank lifted its stake in AbbVie by 6.0% in the third quarter. Baker Boyer National Bank now owns 1,583 shares of the company’s stock valued at $367,000 after buying an additional 89 shares in the last quarter. Finally, Bank of Marin boosted its holdings in shares of AbbVie by 20.6% in the third quarter. Bank of Marin now owns 1,923 shares of the company’s stock valued at $445,000 after buying an additional 328 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Down 0.0%

Shares of ABBV opened at $225.53 on Wednesday. The company’s fifty day simple moving average is $224.20 and its 200 day simple moving average is $219.16. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The company has a market cap of $398.60 billion, a price-to-earnings ratio of 170.86, a PEG ratio of 0.93 and a beta of 0.35.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Regulatory progress: AbbVie submitted applications to the FDA and EMA seeking approval for upadacitinib (RINVOQ) in adults and adolescents with vitiligo after positive Phase 3 Viti‑Up results. Approval would create the first systemic treatment option for vitiligo and materially expand RINVOQ’s addressable market. AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) in Adults and Adolescents With Vitiligo
• Positive Sentiment: Post‑Humira growth roadmap: Management is emphasizing growth from RINVOQ label expansion and cell therapy investments to replace declining Humira sales — a strategic narrative investors view as critical to sustaining revenue and EPS over the medium term. AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion
• Positive Sentiment: Analyst tone ahead of Q4 is constructive: Several previews and analyst notes expect a return to profit and cite Skyrizi/RINVOQ strength, prompting some buy recommendations ahead of earnings. Positive analyst positioning can support the stock into the report. Buy AbbVie Stock Before Q4 Earnings? Here’s What to Know
• Positive Sentiment: Market narratives remain bullish on long-term upside and dividend quality after AbbVie navigated the Humira patent cliff — supporting investor confidence in total returns. 2 Healthcare Dividend Stocks That are Just What the Doctor Ordered
• Neutral Sentiment: Earnings preview/expectations: Multiple previews (Seeking Alpha, MarketWatch, Yahoo) expect revenue growth and a Q4 swing to profit — the print and management commentary will be the immediate catalyst for volatility. AbbVie Q4 Preview: Here’s what to expect
• Neutral Sentiment: Marketing/business updates are ongoing but lower impact: Allergan Aesthetics and migraine education campaigns support brand and aesthetics business engagement, but are unlikely to move near‑term revenue materially. Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
• Negative Sentiment: Relative performance concerns: Data show AbbVie underperformed some peers despite intraday gains, a signal that investors are weighing competitive dynamics and pipeline execution versus peers. Short‑term flows could pressure the stock if the upcoming print disappoints. AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains
• Negative Sentiment: Policy and pricing risk: Coverage on a large drug‑pricing pact and broader policy shifts highlights ongoing pricing/regulatory risks that could weigh on long‑term margins if unfavorable terms or reimbursement pressures intensify. Monitor policy developments closely. AbbVie’s US$100b Drug Pricing Pact Reshapes Growth And Policy Outlook

Analyst Ratings Changes

A number of brokerages recently commented on ABBV. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Guggenheim increased their price objective on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a research note on Tuesday, November 4th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $251.17.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.